Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ptc Therapeutics (PTCT) Other Non-Current Assets: 2012-2024

Historic Other Non-Current Assets for Ptc Therapeutics (PTCT) over the last 13 years, with Dec 2024 value amounting to $20.7 million.

  • Ptc Therapeutics' Other Non-Current Assets fell 23.28% to $19.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $19.4 million, marking a year-over-year decrease of 23.28%. This contributed to the annual value of $20.7 million for FY2024, which is 42.88% down from last year.
  • According to the latest figures from FY2024, Ptc Therapeutics' Other Non-Current Assets is $20.7 million, which was down 42.88% from $36.2 million recorded in FY2023.
  • Over the past 5 years, Ptc Therapeutics' Other Non-Current Assets peaked at $60.6 million during FY2020, and registered a low of $20.7 million during FY2024.
  • Over the past 3 years, Ptc Therapeutics' median Other Non-Current Assets value was $36.2 million (recorded in 2023), while the average stood at $35.2 million.
  • Its Other Non-Current Assets has fluctuated over the past 5 years, first skyrocketed by 269.31% in 2020, then plummeted by 42.88% in 2024.
  • Over the past 5 years, Ptc Therapeutics' Other Non-Current Assets (Yearly) stood at $60.6 million in 2020, then dropped by 23.30% to $46.5 million in 2021, then increased by 4.48% to $48.6 million in 2022, then fell by 25.39% to $36.2 million in 2023, then slumped by 42.88% to $20.7 million in 2024.